Reduced-dose craniospinal irradiation for central nervous system relapsed neuroblastoma.
Leo Y LuoKim KramerNai-Kong V CheungBrian H KushnerShakeel ModakEllen M BasuStephen S RobertsSuzanne L WoldenPublished in: Pediatric blood & cancer (2020)
For patients with CNS-relapsed neuroblastoma, CNS disease control is comparable between 18 Gy and 21 Gy CSI dose regimens, in conjunction with radioimmunotherapy and CNS penetrating chemotherapy. More than 65% of the patients remain CNS disease free after 5 years. The findings support 18 Gy as the new standard CSI dose for CNS-relapsed neuroblastoma.
Keyphrases
- blood brain barrier
- acute lymphoblastic leukemia
- acute myeloid leukemia
- multiple myeloma
- hodgkin lymphoma
- diffuse large b cell lymphoma
- end stage renal disease
- chronic kidney disease
- ejection fraction
- newly diagnosed
- prognostic factors
- squamous cell carcinoma
- radiation therapy
- patient reported outcomes
- radiation induced